This page is part of the FHIR Specification (v4.5.0: R5 Preview #3). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B
Biomedical Research and Regulation Work Group | Maturity Level: N/A | Standards Status: Informative | Compartments: Not linked to any defined compartments |
Raw JSON (canonical form + also see JSON Format Specification)
Simple version of a product (more than basic), only using MedicinalProductDefinition, Ingredient and RegulatedAuthorization
{ "resourceType": "MedicinalProductDefinition", "id": "equilidem-with-ing-and-auth", "text": { "status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative</b></p><p><b>id</b>: equilidem-with-ing-and-auth</p><p><b>identifier</b>: id: Equilidem25</p><p><b>combinedPharmaceuticalDoseForm</b>: <span>tablet</span></p><p><b>indication</b>: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.</p><p><b>legalStatusOfSupply</b>: <span>Prescription only medicine</span></p><p><b>classification</b>: <span>B01A</span></p><p><b>ingredient</b>: </p><ul><li><a> </a></li><li><a> </a></li></ul><blockquote><p><b>id</b>: EquilidoniumPhosphate</p><p><b>role</b>: <span>active</span></p><blockquote><p><b>substance</b></p><p><b>code</b>: <span>Equilidonium Phosphate</span></p><h3>Strengths</h3><table><tr><td>-</td><td><b>Presentation</b></td></tr><tr><td>*</td><td>22 ml/1 tablet</td></tr></table></blockquote></blockquote><blockquote><p><b>id</b>: CalciumCarbonate</p><p><b>role</b>: <span>excipient</span></p><blockquote><p><b>substance</b></p><p><b>code</b>: <span>Calcium Carbonate</span></p><h3>Strengths</h3><table><tr><td>-</td><td><b>Presentation</b></td></tr><tr><td>*</td><td>3 ml/1 tablet</td></tr></table></blockquote></blockquote><h3>Names</h3><table><tr><td>-</td><td><b>ProductName</b></td></tr><tr><td>*</td><td>Equilidem 2.5 mg film-coated tablets</td></tr></table><h3>CrossReferences</h3><table><tr><td>-</td><td><b>Product</b></td></tr><tr><td>*</td><td/></tr></table><h3>ManufacturingBusinessOperations</h3><table><tr><td>-</td><td><b>Manufacturer</b></td></tr><tr><td>*</td><td><span>EquiliDrugCo Processing Inc.</span></td></tr></table></div>" }, "contained": [ { "resourceType": "Ingredient", "id": "EquilidoniumPhosphate", "role": { "coding": [ { "system": "http://example.org.uk/fhir/ingredientType", "code": "active" } ] }, "substance": { "codeCodeableConcept": { "coding": [ { "system": "http://example.org.uk/fhir/substances", "code": "123456", "display": "Equilidonium Phosphate" } ] }, "strength": [ { "presentation": { "numerator": { "value": 22, "unit": "ml" }, "denominator": { "value": 1, "unit": "tablet" } } } ] } }, { "resourceType": "Ingredient", "id": "CalciumCarbonate", "role": { "coding": [ { "system": "http://example.org.uk/fhir/ingredientType", "code": "excipient" } ] }, "substance": { "codeCodeableConcept": { "coding": [ { "system": "http://example.org.uk/fhir/substances", "code": "456789", "display": "Calcium Carbonate" } ] }, "strength": [ { "presentation": { "numerator": { "value": 3, "unit": "ml" }, "denominator": { "value": 1, "unit": "tablet" } } } ] } } ], "identifier": [ { "system": "http://example.org.uk/fhir/product", "value": "Equilidem25" } ], "combinedPharmaceuticalDoseForm": { "coding": [ { "system": "http://example.org.uk/fhir/dosefom", "code": "tablet" } ] }, "indication": "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.", "legalStatusOfSupply": { "coding": [ { "system": "http://example.org.uk/fhir/legalstatusofsupply", "code": "POM", "display": "Prescription only medicine" } ] }, "classification": [ { "coding": [ { "system": "http://www.whocc.no/atc/example", "code": "B01A" } ] } ], "ingredient": [ { "reference": "#EquilidoniumPhosphate" }, { "reference": "#CalciumCarbonate" } ], "name": [ { "productName": "Equilidem 2.5 mg film-coated tablets" } ], "crossReference": [ { "product": { "reference": { "reference": "MedicinalProductDefinition/genericEquilidonium" } } } ], "manufacturingBusinessOperation": [ { "manufacturer": [ { "display": "EquiliDrugCo Processing Inc." } ] } ] }
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.